PTC Therapeutics (PTCT) Provides Regulatory Updates
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/26/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
PTC Therapeutics Provides Key Regulatory Updates
March 19, 2024 7:30 AM EDT-Â BLA submitted to FDA for Upstaza for the treatment of AADC deficiency -
-Â NDA to be submitted mid-year for Translarna based on FDA feedback -
SOUTHÂ PLAINFIELD, N.J., March 19, 2024 /PRNewswire/ --Â PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the submission of a BLA to the U.S. FDA for Upstaza (eladocagene exuparvovec), a gene therapy for the treatment of... More



